Growth / Secretagogue
CJC-1295 / Ipamorelin
A GHRH analogue paired with a selective ghrelin receptor agonist for somatotropic research.
- Research domain
- Growth
- Presentation
- 5 mg + 5 mg / vial
- Assayed purity
- 99.33%
- Evidence base
- Established
Also designatedCJC-1295 no-DAC with Ipamorelin · GHRH analogue blend · CJC-1295 · Ipamorelin
Quick facts
- Purity specification
- ≥ 99% by HPLC
- Physical form
- Lyophilised powder
- Presentation
- 5 mg + 5 mg / vial
- Evidence base
- Established
- Intended use
- Laboratory research only
Current batch · EVN-CJC-2605
Northgate Bioanalytical, 19 May 2026. Assayed content 4.96 mg + 5.08 mg / 5 mg + 5 mg.
View certificateResearch overview
How it is characterised
This preparation combines CJC-1295, a synthetic analogue of growth hormone-releasing hormone modified at four positions to resist enzymatic cleavage, with Ipamorelin, a selective pentapeptide agonist at the growth hormone secretagogue receptor GHS-R1a. The literature examines the two mechanisms as complementary inputs to the somatotropic axis, and Ipamorelin specifically for its selectivity relative to earlier secretagogues.
Mechanism
CJC-1295 is characterised as engaging the GHRH receptor on somatotrophs, raising cyclic AMP and increasing the amplitude of secretory pulses. Ipamorelin is described as acting at GHS-R1a through a distinct Gq-coupled route, without the cortisol and prolactin cross-reactivity reported for earlier secretagogues. The two inputs are studied as additive rather than redundant.
Applications
- Somatotropic axis research
- Neuroendocrine model characterisation
- Receptor selectivity assays
- Comparative secretagogue studies
Research focus
Areas of published investigation
The following describe where this compound has been examined in the scientific literature. They are not claims of effect, and nothing here should be read as a therapeutic indication.
- 01GHRH receptor signalling
- 02GHS-R1a selectivity profiling
- 03Pulsatile secretion patterns
- 04IGF-1 axis characterisation
Research compatibility
Frequently co-studied
Compounds that appear alongside CJC-1295 / Ipamorelin in the published record, and the reason the literature examines them together.
- TesamorelinThe standard comparison: a combined receptor input examined against a single GHRH-receptor analogue.
- NAD+Examined together in models linking growth signalling to mitochondrial capacity.
- BPC-157 + TB-500Paired where growth factor receptor expression is the shared measurement.
Included in research stacks
Molecular & pharmacokinetic data
The physical record
Verify every figure against the certificate of analysis for the batch you hold. Where the label and the assay disagree, the assay is the number to calculate from.
- CAS number
- 863288-34-0 / 170851-70-4
- Molecular formula
- C₁₅₂H₂₅₂N₄₄O₄₂ / C₃₈H₄₉N₉O₅
- Molar mass
- ≈ 3367.80 / 711.85 g/mol
- Reported half-life
- ≈ 30 min (CJC-1295 no-DAC) / ≈ 2 h (Ipamorelin)
- Solubility
- Soluble in bacteriostatic water
Analytical record
Batch EVN-CJC-2605
Analysed by Northgate Bioanalytical, ISO/IEC 17025 accredited, under accession NGB-26-0517. The certificate is retrievable from the issuing laboratory independently of us.
Full certificate- Purity
- 99.33% (combined principal peaks)RP-HPLC, UV 214 nm · spec ≥ 99.0%
- Identity
- 3367.9 Da / 711.7 Da (theoretical 3367.8 / 711.9)ESI-MS · spec Conforms to theoretical mass
- Assayed content
- 99.2% / 101.6% of labelRP-HPLC against reference standard · spec 95.0 – 110.0% of label
- Water content
- 3.8%Karl Fischer titration · spec ≤ 8.0%
- Residual solvents
- Acetonitrile 112 ppm; TFA 58 ppmHeadspace GC-FID · spec Within USP <467> limits
- Appearance
- White lyophilised cakeVisual inspection · spec Conforms
Storage
Store lyophilised at −20 °C, protected from light and moisture. Following reconstitution, hold at 2–8 °C and use within the interval stated on the batch certificate of analysis.
Handling
Allow the vial to reach ambient temperature before breaking the seal so atmospheric moisture does not condense onto the cake. Introduce diluent slowly against the vial wall rather than directly onto the powder, and swirl rather than shake. Avoid repeated freeze-thaw cycles; aliquot where a preparation will be drawn on more than once.
Packaging
Amber borosilicate vial with butyl stopper and aluminium crimp seal, presented in a matte debossed box with die-cut foam insert and magnetic closure.
Selected references
The published record
A starting point rather than a survey. Entries are listed for orientation and do not constitute endorsement of any interpretation drawn from them.
- 01Ipamorelin, the first selective growth hormone secretagogueEuropean Journal of Endocrinology, 1998
- 02CJC-1295 and sustained GHRH receptor activationJournal of Clinical Endocrinology & Metabolism, 2006
- 03Pulsatility in the somatotropic axisEndocrine Reviews, 2016
This catalogue is presented for informational purposes only. It is not an offer of sale, and it makes no medical or therapeutic claim.
You may also be studying
Enquiries
Request the batch documentation.
Ask a specialist about CJC-1295 / Ipamorelin — its current batch, analytical documentation, and what can be supplied to your territory.